Poseida Book Value Per Share from 2010 to 2024

PSTX Stock

USD 9.33 0.05 0.53%

Poseida Therapeutics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share will likely drop to 0.71 in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of Poseida Therapeutics according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

1.14986849

Current Value

0.71

Quarterly Volatility

2.41888974

Credit Downgrade

Yuan Drop

Covid

Check Poseida Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Poseida Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 9.1 M, Income Tax Expense of 112.3 K or Tax Provision of 112.3 K, as well as many indicators such as Price To Sales Ratio of 4.45, Dividend Yield of 0.0 or PTB Ratio of 4.84. Poseida financial statements analysis is a perfect complement when working with Poseida Therapeutics Valuation or Volatility modules.

Check out the analysis of Poseida Therapeutics Correlation against competitors.

For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.

Latest Poseida Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of Poseida Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. Poseida Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Poseida Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0.90 X

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Book Value Per Share

Timeline

Poseida Book Value Per Share Regression Statistics

	Arithmetic Mean	0.63
	Coefficient Of Variation	383.80
	Mean Deviation	1.48
	Median	0.28
	Standard Deviation	2.42
	Sample Variance	5.85
	Range	11.0403
	R-Value	0.26
	Mean Square Error	5.87
	R-Squared	0.07
	Significance	0.35
	Slope	0.14
	Total Sum of Squares	81.91

Poseida Book Value Per Share History

	2024	0.71
	2023	1.15
	2022	2.61
	2021	2.51
	2020	7.28
	2019	-3.76
	2018	-2.14

Other Fundumenentals of Poseida Therapeutics

Tangible Book Value Per Share

Poseida Therapeutics Book Value Per Share component correlations

	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Long Term Debt	Good Will	Total Liab	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Intangible Assets	Deferred Long Term Liab	Capital Stock	Short Term Investments	Long Term Debt Total	Capital Surpluse
Net Tangible Assets		-0.83	0.2	0.61	0.83	0.84	0.72	0.85	0.94	0.69	0.13	0.72	-0.53	0.13	0.95	0.51	0.82	0.81	-0.57	0.71	0.88	0.79	0.61	0.65
Retained Earnings	-0.83		-0.52	-0.75	-0.85	-0.93	-0.8	-0.88	-0.7	-0.82	-0.07	-0.93	0.68	-0.58	-0.76	-0.78	-0.82	-0.84	0.84	-0.9	-0.94	-0.69	-0.79	-0.84
Accounts Payable	0.2	-0.52		0.05	0.4	0.4	0.79	0.43	0.19	0.17	-0.7	0.4	-0.18	0.53	0.23	0.6	0.37	0.6	-0.61	0.32	0.35	-0.16	0.12	0.21
Net Receivables	0.61	-0.75	0.05		0.56	0.79	0.33	0.56	0.45	0.7	0.53	0.84	-0.55	0.36	0.53	0.44	0.49	0.46	-0.45	0.9	0.83	0.68	0.98	0.94
Total Current Assets	0.83	-0.85	0.4	0.56		0.91	0.82	1.0	0.86	0.81	-0.13	0.87	-0.3	0.56	0.9	0.82	0.99	0.92	-0.82	0.6	0.88	0.81	0.6	0.58
Common Stock	0.84	-0.93	0.4	0.79	0.91		0.79	0.91	0.8	0.86	0.06	0.96	-0.42	0.49	0.86	0.8	0.86	0.84	-0.78	0.8	0.99	0.77	0.85	0.84
Property Plant Equipment	0.72	-0.8	0.79	0.33	0.82	0.79		0.83	0.75	0.52	-0.51	0.69	-0.25	0.42	0.77	0.74	0.8	0.91	-0.74	0.53	0.75	0.38	0.4	0.46
Total Assets	0.85	-0.88	0.43	0.56	1.0	0.91	0.83		0.86	0.81	-0.12	0.87	-0.34	0.55	0.9	0.82	0.99	0.93	-0.83	0.63	0.89	0.8	0.6	0.6
Total Stockholder Equity	0.94	-0.7	0.19	0.45	0.86	0.8	0.75	0.86		0.59	-0.08	0.64	-0.21	0.06	0.99	0.52	0.86	0.85	-0.52	0.51	0.8	0.76	0.47	0.46
Current Deferred Revenue	0.69	-0.82	0.17	0.7	0.81	0.86	0.52	0.81	0.59		0.31	0.89	-0.5	0.63	0.66	0.83	0.78	0.61	-0.83	0.67	0.84	0.86	0.78	0.79
Net Debt	0.13	-0.07	-0.7	0.53	-0.13	0.06	-0.51	-0.12	-0.08	0.31		0.14	-0.49	-0.11	-0.05	-0.21	-0.13	-0.32	0.14	0.37	0.14	0.43	0.46	0.44
Long Term Debt	0.72	-0.93	0.4	0.84	0.87	0.96	0.69	0.87	0.64	0.89	0.14		-0.47	0.66	0.72	0.84	0.82	0.77	-0.83	0.84	0.95	0.75	0.89	0.87
Good Will	-0.53	0.68	-0.18	-0.55	-0.3	-0.42	-0.25	-0.34	-0.21	-0.5	-0.49	-0.47		-0.32	-0.26	-0.27	-0.29	-0.28	0.44	-0.78	-0.51	-0.4	-0.52	-0.66
Total Liab	0.13	-0.58	0.53	0.36	0.56	0.49	0.42	0.55	0.06	0.63	-0.11	0.66	-0.32		0.15	0.77	0.55	0.43	-0.79	0.4	0.43	0.34	0.42	0.43
Net Invested Capital	0.95	-0.76	0.23	0.53	0.9	0.86	0.77	0.9	0.99	0.66	-0.05	0.72	-0.26	0.15		0.59	0.89	0.88	-0.59	0.58	0.86	0.79	0.55	0.54
Short Long Term Debt	0.51	-0.78	0.6	0.44	0.82	0.8	0.74	0.82	0.52	0.83	-0.21	0.84	-0.27	0.77	0.59		0.79	0.76	-0.97	0.51	0.73	0.56	0.54	0.55
Net Working Capital	0.82	-0.82	0.37	0.49	0.99	0.86	0.8	0.99	0.86	0.78	-0.13	0.82	-0.29	0.55	0.89	0.79		0.92	-0.81	0.55	0.83	0.81	0.53	0.51
Short Term Debt	0.81	-0.84	0.6	0.46	0.92	0.84	0.91	0.93	0.85	0.61	-0.32	0.77	-0.28	0.43	0.88	0.76	0.92		-0.79	0.61	0.82	0.6	0.47	0.48
Intangible Assets	-0.57	0.84	-0.61	-0.45	-0.82	-0.78	-0.74	-0.83	-0.52	-0.83	0.14	-0.83	0.44	-0.79	-0.59	-0.97	-0.81	-0.79		-0.6	-0.73	-0.58	-0.53	-0.56
Deferred Long Term Liab	0.71	-0.9	0.32	0.9	0.6	0.8	0.53	0.63	0.51	0.67	0.37	0.84	-0.78	0.4	0.58	0.51	0.55	0.61	-0.6		0.86	0.59	0.88	0.92
Capital Stock	0.88	-0.94	0.35	0.83	0.88	0.99	0.75	0.89	0.8	0.84	0.14	0.95	-0.51	0.43	0.86	0.73	0.83	0.82	-0.73	0.86		0.79	0.87	0.88
Short Term Investments	0.79	-0.69	-0.16	0.68	0.81	0.77	0.38	0.8	0.76	0.86	0.43	0.75	-0.4	0.34	0.79	0.56	0.81	0.6	-0.58	0.59	0.79		0.68	0.63
Long Term Debt Total	0.61	-0.79	0.12	0.98	0.6	0.85	0.4	0.6	0.47	0.78	0.46	0.89	-0.52	0.42	0.55	0.54	0.53	0.47	-0.53	0.88	0.87	0.68		0.97
Capital Surpluse	0.65	-0.84	0.21	0.94	0.58	0.84	0.46	0.6	0.46	0.79	0.44	0.87	-0.66	0.43	0.54	0.55	0.51	0.48	-0.56	0.92	0.88	0.63	0.97

Click cells to compare fundamentals

About Poseida Therapeutics Financial Statements

Poseida Therapeutics investors use historical fundamental indicators, such as Poseida Therapeutics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Poseida Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	1.15	0.71
Tangible Book Value Per Share	1.09	0.61

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC